The lactate-NAD
AP-1
CP: Cancer
NAD(+)/NADH
PARP inhibitors
SQSTM1
cancer metabolism
cancer-associated fibroblasts
olaparib
p62
poly(ADP-ribose)-polymerase 1
stroma
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
10 05 2022
10 05 2022
Historique:
received:
04
11
2021
revised:
14
03
2022
accepted:
14
04
2022
entrez:
11
5
2022
pubmed:
12
5
2022
medline:
18
5
2022
Statut:
ppublish
Résumé
Reduced p62 levels are associated with the induction of the cancer-associated fibroblast (CAF) phenotype, which promotes tumorigenesis in vitro and in vivo through inflammation and metabolic reprogramming. However, how p62 is downregulated in the stroma fibroblasts by tumor cells to drive CAF activation is an unresolved central issue in the field. Here we show that tumor-secreted lactate downregulates p62 transcriptionally through a mechanism involving reduction of the NAD
Identifiants
pubmed: 35545049
pii: S2211-1247(22)00559-9
doi: 10.1016/j.celrep.2022.110792
pmc: PMC9136538
mid: NIHMS1806835
pii:
doi:
Substances chimiques
Poly(ADP-ribose) Polymerase Inhibitors
0
NAD
0U46U6E8UK
Lactic Acid
33X04XA5AT
Poly(ADP-ribose) Polymerases
EC 2.4.2.30
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
110792Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA030199
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA211024
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA252146
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA250025
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA218254
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA234245
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA265892
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA246765
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014195
Pays : United States
Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests J.F.L., T.C.-D., J.M., and M.T.D.-M. are coinventors of a patent issued to Weill Cornell Medical College of Cornell University on “activation of the stroma by PARP-1 inhibitors.” J.M. and M.T.D.-M. are co-founders of Zelambio. O.E. is a scientific adviser and equity holder in Freenome, Owkin, Volastra Therapeutics, and OneThree Biotech. C.M.M. is a member of the Advisory Board of Cell Reports. All other authors declare no competing interests.
Références
Nat Rev Mol Cell Biol. 2012 Jun 20;13(7):411-24
pubmed: 22713970
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Res. 2006 Aug 15;66(16):8109-15
pubmed: 16912188
Cell. 2009 Jun 12;137(6):1001-4
pubmed: 19524504
Nat Rev Clin Oncol. 2015 Jan;12(1):27-41
pubmed: 25286972
Nat Cell Biol. 2019 Mar;21(3):397-407
pubmed: 30778219
Cancer Cell. 2020 Aug 10;38(2):279-296.e9
pubmed: 32679108
Cancer Cell. 2017 Oct 9;32(4):474-489.e6
pubmed: 29017058
Trends Biochem Sci. 2019 Feb;44(2):153-166
pubmed: 30473428
N Engl J Med. 2020 Dec 10;383(24):2345-2357
pubmed: 32955174
J Allergy Clin Immunol. 2021 Jun;147(6):2386-2393.e4
pubmed: 33675820
Differentiation. 2002 Dec;70(9-10):473-85
pubmed: 12492490
Mol Cell. 2011 Oct 7;44(1):134-46
pubmed: 21981924
Genome Biol. 2019 Feb 26;20(1):45
pubmed: 30808370
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Front Pharmacol. 2020 May 12;11:656
pubmed: 32477131
Sci Rep. 2019 Oct 4;9(1):14354
pubmed: 31586112
Sci Signal. 2017 May 23;10(480):
pubmed: 28536297
Mol Cell. 2015 Jun 18;58(6):925-34
pubmed: 26091341
Cancer Cell. 2008 Apr;13(4):343-54
pubmed: 18394557
Trends Cell Biol. 2015 Apr;25(4):198-213
pubmed: 25540894
Cell. 2016 Oct 20;167(3):606-609
pubmed: 27768885
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
Cell Metab. 2021 Jun 1;33(6):1076-1087
pubmed: 33930322
Endocr Relat Cancer. 2012 Oct 30;19(6):R187-204
pubmed: 22930558
Carcinogenesis. 2014 Nov;35(11):2592-601
pubmed: 25173886
Dev Cell. 2021 Jan 11;56(1):95-110.e10
pubmed: 33207226
Cancer Cell. 2016 Jun 13;29(6):935-948
pubmed: 27211490
Ann Oncol. 2019 Sep 1;30(9):1437-1447
pubmed: 31218365
Immunity. 2018 Dec 18;49(6):1132-1147.e7
pubmed: 30552022
Mol Aspects Med. 2013 Apr-Jun;34(2-3):337-49
pubmed: 23506875
Cancer Cell. 2018 Apr 9;33(4):770-784.e6
pubmed: 29634950
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
J Mol Cell Cardiol. 2009 Jan;46(1):25-32
pubmed: 19027749
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
Trends Mol Med. 2017 Oct;23(10):899-916
pubmed: 28899755
Cancer Cell. 2016 Sep 12;30(3):418-431
pubmed: 27622334
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
Cancer Cell. 2014 Jul 14;26(1):121-135
pubmed: 25002027
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Cell Rep. 2019 Apr 2;27(1):199-212.e5
pubmed: 30943401
Mol Cell. 2010 May 28;38(4):576-89
pubmed: 20513432
Cell. 2013 Aug 29;154(5):1060-1073
pubmed: 23993096
Cell Metab. 2017 Dec 5;26(6):817-829.e6
pubmed: 28988820
Cancer Cell. 2012 Jan 17;21(1):105-20
pubmed: 22264792
Nat Commun. 2018 Mar 29;9(1):1286
pubmed: 29599478
Elife. 2019 Nov 01;8:
pubmed: 31663852
Clin Cancer Res. 2018 Feb 1;24(3):696-707
pubmed: 29138344
Trends Cell Biol. 2013 Dec;23(12):593-602
pubmed: 24074947
Clin Cancer Res. 2019 Nov 15;25(22):6839-6851
pubmed: 31439587
J Biol Chem. 2010 Jul 16;285(29):22576-91
pubmed: 20452972
Cancer Res. 2000 Feb 15;60(4):916-21
pubmed: 10706105
Biochim Biophys Acta Rev Cancer. 2018 Aug;1870(1):88-95
pubmed: 29702207
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
Cell Metab. 2018 Apr 3;27(4):757-785
pubmed: 29617642
Cancer Cell. 2016 Oct 10;30(4):595-609
pubmed: 27728806
Nat Rev Mol Cell Biol. 2021 Feb;22(2):119-141
pubmed: 33353981
Nature. 2019 May;569(7758):723-728
pubmed: 31043742